XML 86 R30.htm IDEA: XBRL DOCUMENT

Restructuring and Asset Impairment Charges (Tables)

9 Months Ended

Dec. 31, 2019

Restructuring and Related Activities [Abstract]

Restructuring, Impairment and Related Costs

Restructuring, Impairment and Related Charges for the Company’s fiscal 2019 initiatives during the three and nine months ended December 31, 2019 consisted of the following:



	Three Months Ended December 31, 2019
(In millions)	U.S. Pharmaceutical and Specialty Solutions		European Pharmaceutical Solutions		Medical-Surgical Solutions		Other		Corporate		Total
Severance and employee-related costs, net	$	3	$	1	$	1	$	—	$	7	$	12
Exit and other-related costs ⁽¹⁾	—		2		5		—		13		20
Asset impairments and accelerated depreciation	—		2		—		—		3		5
Total	$	3	$	5	$	6	$	—	$	23	$	37



	Nine Months Ended December 31, 2019
(In millions)	U.S. Pharmaceutical and Specialty Solutions		European Pharmaceutical Solutions		Medical-Surgical Solutions		Other		Corporate		Total
Severance and employee-related costs, net	$	4	$	3	$	2	$	1	$	23	$	33
Exit and other-related costs ⁽¹⁾	—		7		9		1		36		53
Asset impairments and accelerated depreciation	—		8		1		—		8		17
Total	$	4	$	18	$	12	$	2	$	67	$	103


(1)	Exit and other-related costs primarily include project consulting fees.

Restructuring, impairment and related charges for the Company’s fiscal 2019 initiatives during the three and nine months ended December 31, 2018 consisted of the following:



	Three Months Ended December 31, 2018
(In millions)	U.S. Pharmaceutical and Specialty Solutions		European Pharmaceutical Solutions		Medical-Surgical Solutions		Other		Corporate		Total
Severance and employee-related costs, net	$	1	$	—	$	—	$	9	$	32	$	42
Exit and other-related costs ⁽¹⁾	1		4		5		—		16		26
Asset impairments and accelerated depreciation	2		—		1		—		—		3
Total	$	4	$	4	$	6	$	9	$	48	$	71



	Nine Months Ended December 31, 2018
(In millions)	U.S. Pharmaceutical and Specialty Solutions		European Pharmaceutical Solutions		Medical-Surgical Solutions		Other		Corporate		Total
Severance and employee-related costs, net	$	4	$	—	$	10	$	16	$	36	$	66
Exit and other-related costs ⁽¹⁾	7		4		12		56		45		124
Asset impairments and accelerated depreciation	6		—		2		17		—		25
Total	$	17	$	4	$	24	$	89	$	81	$	215

(1)

Exit and other-related costs primarily include lease exit costs associated with closures of retail pharmacy stores within the Company’s Canadian business as well as project consulting fees.

Schedule of Restructuring and Asset Impairment Charges

The following table summarizes the activity related to the restructuring liabilities associated with the Company’s fiscal 2019 initiatives for the nine months ended December 31, 2019:



(In millions)	U.S. Pharmaceutical and Specialty Solutions			European Pharmaceutical Solutions			Medical-Surgical Solutions			Other			Corporate			Total
Balance, March 31, 2019 ⁽¹⁾	$	31		$	38		$	15		$	29		$	37		$	150
Restructuring, impairment and related charges	4			18			12			2			67			103
Non-cash charges	—			(8		)	(1		)	—			(8		)	(17		)
Cash payments	(6		)	(13		)	(8		)	(16		)	(43		)	(86		)
Other	(1		)	(4		)	(2		)	(5		)	(6		)	(18		)
Balance, December 31, 2019 ⁽²⁾	$	28		$	31		$	16		$	10		$	47		$	132


(1)	As of March 31, 2019, the total reserve balance was $150 million of which $117 million was recorded in other accrued liabilities and $33 million was recorded in other noncurrent liabilities.

(2)

As of December 31, 2019, the total reserve balance was $132 million of which $110 million was recorded in other accrued liabilities and $22 million was recorded in other noncurrent liabilities.